Batuhan Küçükali

Batuhan Küçükali

Auto-generated profile, based on publicly available information

Batuhan Küçükali

Department of Pediatric Rheumatology, Gazi University Faculty of Medicine , Ankara

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2024 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
BKBatuhan Küçükali
Batuhan Küçükali
EBElif Özlem Bayraktar
Elif Özlem Bayraktar
ÇYÇisem Yıldız
Çisem Yıldız
SGSevim Gönen
Sevim Gönen
MKMerve Kutlar
Merve Kutlar
SBSevcan A. Bakkaloğlu
Sevcan A. Bakkaloğlu
Objective: The exact effects of MEFV variants on inflammation are still under investigation, and reports on variants of unknown significance, particularly the E148Q variant, have been conflicting. Therefore, this study aims to investigate patients exhibiting E148Q heterozygosity, focusing on diagnoses and disease courses to assist physicians in interpreting the variant. Methods: Data of pediatric patients presenting to the Pediatric Rheumatology clinic between November 2016 and September 2023, exhibiting only E148Q heterozygosity in MEFV gene analysis, were extracted. Patients who were lost before 9 months of follow-up have been excluded to ensure the completion of initial diagnostic tests and evaluations. Results: Among the 119 patients with E148Q variant, the diagnoses were as follows: healthy, 51.3%; IgA vasculitis, 10.1%; Familial Mediterranean Fever (FMF), 7.6%; Periodic fever, Aphtous stomatitis, Pharyngitis, Adenitis (PFAPA), 6.7%; and other diagnoses, 19.3%. IgA vasculitis patients experienced articular, gastrointestinal, and renal involvement at rates of 91.7%, 58.3%, and 16.7%, respectively. Complete response, partial response, and no response to colchicine were 37.5%, 12.5%, and 50%, respectively, in PFAPA patients. All FMF patients responded to colchicine treatment resulting in reduced mean FMF episode counts in 6 months from 3.22 ± 0.92 to 0.56 ± 0.52. Conclusions: The E148Q variant may amplify inflammation and modify disease courses. Patients with the E148Q variant experiencing typical FMF episodes should receive colchicine, but clinicians should exercise caution regarding alternative diagnoses. Additionally, the E148Q variant may increase acute phase reactants and disease severity in IgA vasculitis. However, to reach definitive conclusions on its treatment-modifying role in PFAPA, universal diagnosis and treatment response criteria should be adopted.

19 March 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
ÇYÇisem Yıldız
Çisem Yıldız
BKBatuhan Küçükali
Batuhan Küçükali
MKMerve Kutlar
Merve Kutlar
NBNuran Belder
Nuran Belder
NKNihal Karaçayır
Nihal Karaçayır
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU
Juvenile idiopathic arthritis (JIA) presents with diverse phenotypes and can lead to significant morbidity. Obesity, affecting 5 to 23% of JIA patients, may exacerbate disease activity and complicate management. This study evaluates the impact of body mass index (BMI) on disease activity and the influence of joint involvement on BMI in JIA patients. Between January 2012 and June 2024, 225 JIA patients were reviewed, with 173 ultimately included based on specific inclusion and exclusion criteria. Treatments followed the American College of Rheumatology (ACR) recommendations. Data on demographics, BMI, JADAS-27 scores, joint involvement, and laboratory parameters were analyzed, with statistical significance defined as p < 0.05. Among 173 JIA patients, significant increases in weight and height SDS were observed (p < 0.05). Obese patients at baseline had higher JADAS-27 scores at 6 months (p < 0.05). A positive correlation was found between initial JADAS-27 and final BMI SDS (r = 0.170, p < 0.05). Patients with hip involvement had lower BMI at diagnosis and at the first-year follow-up (p < 0.0001, p = 0.049), while knee involvement was linked to lower height SDS at the second year (p = 0.041). Conclusion: Our study revealed that baseline obesity is a significant risk factor for poorer disease control at the 6-month follow-up in JIA patients. We also observed that effective treatment led to improvements in growth, particularly in patients with hip involvement, who initially had lower BMI values. These findings underscore the importance of monitoring BMI in JIA patients to optimize disease management and long-term outcomes. What is Known:• Overweight and obesity are prevalent in children with JIA, with reported rates ranging from 5 to 23% in various studies.• The relationship between BMI and disease activity in JIA remains controversial, with previous studies reporting conflicting results on whether BMI impacts disease remission or activity. What is New:• Baseline obesity in juvenile idiopathic arthritis (JIA) patients is associated with worse disease activity during follow-up, particularly evident at the 6-month visit.• Patients with hip involvement had significantly lower BMI values, indicating a potential correlation with more severe disease.• Improved linear growth was observed in JIA patients during follow-up, indicating that effective treatment positively impacts growth despite the chronic nature of the disease.

30 January 2025 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
BKBatuhan Küçükali
Batuhan Küçükali
ÇYÇisem Yıldız
Çisem Yıldız
BGBuğra Taygun Gülle
Buğra Taygun Gülle
DYDeniz Gezgin Yıldırım
Deniz Gezgin Yıldırım
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU
Objectives: The International League of Associations for Rheumatology (ILAR) juvenile idiopathic arthritis (JIA) classification was revisited by the Pediatric Rheumatology International Trials Organization (PRINTO) in 2018. Classifications should establish uniform groups to assist physicians in providing optimal care. Therefore, we evaluated changes proposed by PRINTO to highlight their impact on forming consistent groups regarding uveitis and treatment responses, particularly focusing on early-onset anti-nuclear antibody (ANA)-positive JIA. Methods: Pediatric patients diagnosed with JIA according to ILAR and PRINTO classification, with a minimum of 1-year of follow-up, were enrolled, excluding those meeting the exclusion criteria for both the oligoarticular JIA and the early-onset ANA-positive JIA groups. Results: Among the 139 enrolled patients, 110 (79.1%) had oligoarticular JIA, while 15 (10.8%) had early-onset ANA-positive JIA. The below-age-5 criterion demonstrated the strongest association with uveitis, while the below-age-7 provided similar associations without substantial exclusions (odds ratio (OR) 8.62 [2.50–29.81] vs 7.45 [2.37–26.66]). Patients with a single ANA positivity at a titer ≥ 1/160 and age of onset below 7 had a notably higher risk of new-onset uveitis and biologic DMARD requirement (OR 7.95 [2.37–26.66] and 3.6 [1.42–9.09], respectively). Conclusion: The inclusion of age of disease onset and ANA positivity with a titer ≥ 1/160 has enhanced uniformity in uveitis risk and treatment response, including failure of conventional synthetic DMARDs. Additionally, a single ANA positivity at a ≥ 1/160 titer rather than requiring two instances yields similar consistency. However, the joint count criteria failed to form consistent groups. PRINTO’s classification places a significant proportion of patients into the “other JIA” group, necessitating further classification for improved clinical utility. Key Points•Inclusion of age and ANA positivity criteria increased uniformity among the subgroups.•Single ANA positivity at a ≥ 1/160 titer can be sufficient instead of twice.•Early utilization of bDMARDs may be beneficial for early-onset ANA-positive JIA group.•PRINTO classification must further classify the “other JIA” before being implemented in clinical practice.

17 October 2023 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
BKBatuhan Küçükali
Batuhan Küçükali
DYDeniz Gezgin Yıldırım
Deniz Gezgin Yıldırım
PŞPelin Şenol
Pelin Şenol
HOHuseyin Baran Ozdemir
Huseyin Baran Ozdemir
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU

14 October 2024 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
ÇYÇisem Yıldız
Çisem Yıldız
BKBatuhan Küçükali
Batuhan Küçükali
SCSushma Shree B. C.
Sushma Shree B. C.
PŞPelin Şenol
Pelin Şenol
MKMerve Kutlar
Merve Kutlar
SESEVCAN AZIME BAKKALOGLU EZGU
SEVCAN AZIME BAKKALOGLU EZGU

18 August 2026 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
EKElif Kilic Konte
Elif Kilic Konte
SSSezgin Sahin
Sezgin Sahin
ESEsra Firat Sentürk
Esra Firat Sentürk
ABAydan Yekedüz Bülbül
Aydan Yekedüz Bülbül
CACeyda Arslanoglu
Ceyda Arslanoglu
OKOzgur Kasapcopur
Ozgur Kasapcopur